Baseline serum testosterone and differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial
- Published on 06/03/2025
- Reading time: 2 min.
Kanayama Mayuko 1, Tsai Hua-Ling 2, Wang Hao 2, Antonarakis Emmanuel S. 3, Denmeade Samuel R. 1,2, Luo Jun 1,2
1 https://ror.org/00za53h95 Department of Urology, The James Buchanan Brady Urological Institute Johns Hopkins University School of Medicine 600N Wolfe St 21287 Baltimore MD USA
2 https://ror.org/00za53h95 Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine 401N Broadway 21231 Baltimore MD USA
3 https://ror.org/03e1ayz78 Department of Oncology, Masonic Cancer Center University of Minnesota Medical Center 420 Delaware Street SE, MMC 480 55455 Minneapolis MN USA
Abstract
Bipolar androgen therapy (BAT) is effective in a subset of metastatic castration-resistant prostate cancer (mCRPC) patients. Treatment selection biomarkers are needed due to other therapies that can be equally efficacious. We performed post-hoc analysis to determine whether baseline serum testosterone (T) is a treatment selection marker in the TRANSFORMER study, a randomized trial of abiraterone-pretreated mCRPC patients assigned to BAT (n = 94) or enzalutamide...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Psychiatry
Receive our newsletter to stay up to date with the latest news in Psychiatry
